aclidinium vs tiotropium/olodaterol
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of aclidinium and tiotropium/olodaterol. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tudorza Pressair
Stiolto Respimat
No summary available.
Stiolto Respimat combines two medicines to help you breathe better if you have COPD. It is used long-term to manage your COPD symptoms.
Information not available.
Stiolto Respimat is used to treat chronic obstructive pulmonary disease (COPD). This includes chronic bronchitis and emphysema. This medicine helps you breathe better over a long period. Stiolto Respimat is not for sudden COPD symptoms or asthma.
Information not available.
Stiolto Respimat contains two medicines that open your airways. Tiotropium helps to relax the muscles around your airways. Olodaterol is a long-acting beta-agonist (LABA) that also relaxes airway muscles.
- • Upper respiratory infection
- • Headache
- • Back pain
- • Common cold symptoms (nasopharyngitis)
- • Cough
- • Back pain
- Difficulty breathing 1,869
- Inhaler not working correctly 1,281
- Skipped a dose of medicine 1,017
- Asthma 814
- Chronic obstructive pulmonary disease (COPD) 764
No adverse event reports.
No specific warnings noted.
Using LABA medicines like Stiolto Respimat without a steroid medicine can be dangerous if you have asthma. Stiolto Respimat is not meant to treat asthma. Do not use Stiolto Respimat for sudden breathing problems. Using too much Stiolto Respimat can cause serious heart problems and may be fatal. If you have a bad reaction, like swelling or rash, stop using Stiolto Respimat and get medical help.
No pregnancy information available.
Tell your doctor if you are pregnant or plan to become pregnant. Stiolto Respimat should be used during pregnancy only if the benefit outweighs the risk to the baby. It is not known if Stiolto Respimat passes into breast milk.
Also Compare, Nearby Drugs
Compare aclidinium with
Compare tiotropium/olodaterol with
How to Read This aclidinium vs tiotropium/olodaterol Comparison
aclidinium is classified in the Long-Acting Muscarinic Antagonist (LAMA) drug class, while tiotropium/olodaterol sits within the LAMA / LABA Combination class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aclidinium has 5,745 submissions while tiotropium/olodaterol has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for aclidinium or tiotropium/olodaterol.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.